Diclazepam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Diclazepam (2-chlorodiazepam) is a synthetic depressant of the benzodiazepine class. It is the 2′-chloro structural analog of diazepam, distinguished by longer duration and greater sedative weight.[1] Diclazepam is a positive allosteric modulator of GABA-A receptors, producing its effects by amplifying the brain's primary inhibitory signaling system.[2][3]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, alcohol, barbiturates +3 morebenzodiazepines, alcohol, barbiturates, zolpidem, zopiclone, zaleplon show less
Synthesized at Hoffmann-La Roche around 1960 during Leo Sternbach's systematic benzodiazepine exploration, the compound was catalogued as Ro 5-3448 but never advanced to clinical development.[4][2] It resurfaced in 2012 on research chemical markets, becoming one of the earliest designer benzodiazepines to reach widespread availability.[4] Diclazepam is now permanently scheduled in the United States, the European Union, and the United Kingdom.
Subjective effects include sedation, anxiety suppression, muscle relaxation, and thought deceleration. The experience is one of gradual, enveloping calm — anxiety recedes before heavy sedation sets in, creating an early window of functional relief that distinguishes it from more sharply sedating benzodiazepines. Anterograde amnesia, disinhibition, and delusions of sobriety are characteristic unsought effects.
Diclazepam produces physical dependence with repeated use, and reinforcing properties have been confirmed in animal models.[5] Three active metabolites — including delorazepam, with a half-life potentially exceeding 100 hours — create cumulative CNS depression far beyond perceived sobriety; published fatalities involve exclusively polydrug combinations.[6][4] No controlled human studies have been conducted; the current understanding rests on a single self-experiment, forensic case reports, and structural analogy to diazepam.[1]
History[edit]
Discovery
Diclazepam was first synthesized by Leo Sternbach and colleagues at Hoffmann-La Roche around 1960, part of the prolific structure-activity program that produced diazepam, chlordiazepoxide, and dozens of related benzodiazepines.[4][2] Assigned the internal designation Ro 5-3448, the compound was patented alongside numerous analogs but never advanced through clinical development — no pharmacological data were published by Roche, and no pharmaceutical product was ever marketed.[4][2]
Emergence as a designer benzodiazepine
Diclazepam appeared on online research chemical vendor sites in 2012, among the first wave of designer benzodiazepines to enter novel psychoactive substance markets.[4][2][7] The first scientific characterization followed in 2014, when Moosmann, Bisel, and Auwärter at the University of Freiburg published analytical data alongside the only human pharmacokinetic study — a single-person self-experiment.[4]
Regulatory response
Regulatory action followed the compound's proliferation across unregulated markets. Germany scheduled diclazepam in November 2015, the United Kingdom classified it as Class C in June 2017, the European Union adopted control measures in March 2024,[8] and the United States placed it permanently in Schedule I effective April 2026.[9]
The name diclazepam follows standard benzodiazepine nomenclature: the di- prefix references the two chlorine atoms (one at C-7 on the fused ring, one at the 2′-position of the pendant phenyl), while -azepam denotes the seven-membered diazepine ring shared by the classical benzodiazepine family. The alternate names 2-chlorodiazepam and chlorodiazepam describe the compound purely in terms of its structural relationship to diazepam.
Chemistry[edit]
Structure
Diclazepam belongs to the 1,4-benzodiazepin-2-one family, the core scaffold shared by diazepam, nitrazepam, clonazepam, and most classical pharmaceutical benzodiazepines. The structure consists of a benzene ring fused to a seven-membered diazepine ring bearing a carbonyl group at position 2.
Diclazepam is the 2′-chloro structural analog of diazepam: the two compounds share identical substitution at every position except the pendant phenyl ring, where diclazepam carries an additional chlorine at the ortho position.[1] This single halogen addition produces measurably different pharmacological activity despite minimal structural distance.[1]
| Molecular formula | C₁₆H₁₂Cl₂N₂O |
| Molecular weight | 319.2 g/mol |
Stereochemistry
Diclazepam contains no chirality centers and exists as a single constitutional isomer with no stereoisomeric considerations. A forensically relevant note: its positional isomer 4′-chlorodiazepam (Ro5-4864) shares near-identical mass spectral fragmentation patterns, requiring careful chromatographic separation for unambiguous identification.[11]
Physical properties
Diclazepam presents as a white crystalline powder with moderate lipophilicity and low polar surface area — properties that predict favorable oral absorption and efficient crossing of biological membranes.[12] No peer-reviewed melting point or aqueous solubility data have been published. citation needed
Pharmacology[edit]
Mechanism of action
Diclazepam acts as a positive allosteric modulator of the GABA-A, binding at the classical benzodiazepine site between the α and γ₂ subunits.[2][3] It does not activate the receptor directly — instead, it increases the frequency of chloride channel opening when GABA is already present, amplifying the brain's existing inhibitory signals. The result is a broad reduction of neural excitability across the central nervous system.
No direct binding affinity measurements have been published for diclazepam at any GABA-A receptor subtype. Computational modeling predicts potent benzodiazepine-site activity consistent with its structural features — particularly the halogen at C-7 and the electronegative 2′-chlorophenyl group.[13][14][6]
Pharmacokinetics
Diclazepam is administered orally. The half-life is approximately 42 hours, based on a single self-experiment in which one researcher ingested 1 mg and provided samples over 21 days.[4] An independent review estimates approximately 46 hours from the same dataset.[6]
The compound produces three pharmacologically active metabolites: delorazepam (the primary and highest-concentration metabolite, itself a long-acting benzodiazepine), lorazepam, and lormetazepam.[4] The parent compound remained detectable in blood up to 99 hours after a single dose; delorazepam persisted up to 10 days in blood; lorazepam was detectable in urine for up to 19 days.[4]
Oral absorption is expected to be efficient based on the compound's physicochemical profile,[12] though no formal bioavailability data have been published. The specific liver enzymes involved in metabolism have not been characterized, but involvement of CYP3A4 and CYP2C19 is probable based on analogy to diazepam. inferred
Neuroscience[edit]
Where it acts
Diclazepam's effects arise from amplified inhibitory signaling at GABA-A receptors distributed throughout the brain. Enhanced inhibition in the thalamus reduces sensory throughput and promotes sedation. In the amygdala and hippocampus, potentiated GABA currents dampen fear-conditioned responses and suppress anxiety — consistent with the prominent anxiolytic motivation reported by diclazepam users.[10] Hippocampal inhibition also suppresses memory formation, accounting for the anterograde amnesia that extends far beyond perceived intoxication due to the compound's long-acting metabolites.
Why it matters
Diclazepam engages the brain's reward circuitry through disinhibition: by quieting inhibitory interneurons in the ventral tegmental area, it releases dopamine signaling in the mesolimbic pathway.[15] Rodent self-administration studies confirm this reinforcing potential,[5] though the absence of conditioned place preference suggests reinforcement operates more through relief of distress than through pleasure-seeking.[5]
This pattern — wanting the absence of anxiety rather than the presence of euphoria — may explain why self-medication is diclazepam's dominant documented use pattern.[10]
Key unknowns include whether diclazepam preferentially modulates specific GABA-A receptor subtypes (which would determine the balance of sedative, anxiolytic, and amnestic effects), and how its three active metabolites interact at the receptor level during sustained use. Chronic use drives neuroadaptive changes — downregulation, subunit composition shifts, and compensatory excitatory upregulation — that underlie both tolerance and the severity of withdrawal.
Subjective Effects[edit]
The diclazepam experience follows a classical benzodiazepine arc: anxiety dissolves first, followed by progressive sedation, muscle relaxation, and cognitive slowing. At lower doses, this creates a window of functional anxiolysis — relief without incapacitation — that narrows as the dose rises. Higher doses collapse this window into heavy sedation, pronounced amnesia, and a loss of behavioral control the user may not recognize while impaired.
Compared to diazepam, diclazepam is reported as qualitatively similar but longer-acting and more sedating at equivalent doses. Relative to shorter-acting designer benzodiazepines such as etizolam, the onset is slower, the peak less sharply defined, and the functional anxiolytic window broader — characteristics that account for its documented use as a self-medication tool for sustained anxiety suppression and benzodiazepine withdrawal management.[10]
Effect Grid
Clear anxiety suppression and moderate sedation at 1–3 mg. The anxiolytic effect is now unambiguous — worry and tension dissolve noticeably. Thought deceleration becomes apparent: information processing slows, and concentration narrows. Emotional suppression flattens both positive and negative affect. Some anterograde amnesia is possible at the upper end of this range.
Muscle relaxation becomes pronounced. Motor control impairment is mild but measurable — fine motor tasks and balance are affected. Sedation may produce drowsiness, especially in the evening. Dizziness is possible.
Disinhibition and delusions of sobriety are significant risks at common doses. Users may believe themselves fully functional while exhibiting slurred speech, impaired judgment, and ataxia visible to others. The 8–12 hour subjective duration understates true pharmacological exposure due to active metabolites persisting for days.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual acuity suppression · Visual haze / noise · Visual processing suppression
Bodily heaviness · Dizziness · Body high · Nystagmus (eye wobbles) · Nausea
Nausea
Cognitive fatigue · Focus suppression · Information processing suppression · Memory suppression · Memory fragmentation · Thought disorganization · Confusion · Language suppression · Motivation suppression · Suggestibility enhancement · Compulsive redosing urge · Amnesia · Delirium
Memory suppression · Memory fragmentation · Thought disorganization · Confusion · Language suppression · Motivation suppression · Compulsive redosing urge · Amnesia · Delirium
Dysphoria
Depersonalization · Derealization · Cognitive disconnection
Timeline
First perceptible anxiolysis emerges as a subtle loosening of tension. Physical awareness is minimal — slight warmth or relaxation may be noticed.
Anxiolysis deepens and sedation begins to establish. Muscle relaxation becomes noticeable. Thought deceleration starts — the mind quiets progressively.
Full sedation, anxiolysis, and muscle relaxation. Cognitive slowing and amnesia risk are maximal. Disinhibition and delusions of sobriety are prominent at higher doses.
Gradual reduction in perceived sedation. Functional
⚠ impairment persists beyond subjective awareness — the mismatch between felt sobriety and actual impairment drives compulsive redosing risk.
Residual effects from active metabolites produce subtle cognitive impairment and muscle relaxation lasting 12–48 hours. Users may not perceive impairment.
⚠ Do not drive or operate machinery for at least 24 hours after ingestion — active metabolites produce residual impairment that may not be subjectively apparent.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Life-threateningfatal risk
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- benzodiazepines · alcohol · barbiturates
Toxicity
Acute toxicity
No lethal dose data have been published for diclazepam in any species. safety citation needed A single clinical case report of diclazepam overdose exists,[16] but no systematic toxicological profile has been established.
Polydrug fatalities
Published fatalities involving diclazepam occur exclusively in polydrug contexts — typically combinations with opioids or other CNS depressants.[6] Documented cases include death from aspiration of gastric content due to mixed drug toxicity involving the synthetic opioid U-47700,[17] and positional asphyxia in the setting of designer benzodiazepine–stimulant polydrug intoxication.[18]
Designer benzodiazepine mortality occurs almost exclusively when combined with other substances.[6]
Metabolite accumulation
All three primary metabolites (delorazepam, lorazepam, lormetazepam) are pharmacologically active.[4] Delorazepam's half-life may exceed 100 hours, creating cumulative CNS depression that persists far beyond perceived sobriety. The lorazepam metabolite remains detectable in urine up to 19 days after a single dose.[4]
Drug-facilitated crime
The pronounced amnestic and sedative effects, combined with poor detectability on standard immunoassay panels, make diclazepam relevant in drug-facilitated sexual assault contexts.[19][20]
Psychological risks
No controlled studies of diclazepam's psychological effects have been conducted.
Acute risks include anterograde amnesia, disinhibition leading to uncharacteristic or dangerous behavior, delusions of sobriety (the false belief of being functionally sober while significantly impaired), and paradoxical aggression.
Chronic risks include cognitive impairment, emotional suppression, and psychological dependence driven by reliance on the compound to manage anxiety or avoid withdrawal. The extended half-life and active metabolite cascade create particular risk of insidious cumulative impairment where the user does not perceive the degree of sustained depression.
Withdrawal-associated risks include rebound effect anxiety exceeding pre-use baseline, insomnia, depersonalization, and in severe cases, psychosis or suicidal ideation — established at the benzodiazepine class level.[21]
Tolerance and dependence
Benzodiazepine tolerance develops through downregulation and changes in receptor subunit composition.[15] Sedative tolerance typically emerges earlier than anxiolytic tolerance. No diclazepam-specific tolerance timeline data have been published. safety citation needed
Physical and psychological dependence form with repeated use. Reinforcing properties have been confirmed in rodent self-administration studies.[5] Standard urine immunoassays may fail to detect diclazepam, complicating clinical assessment of dependence.[22][23]
A documented paradox: 22.6% of user forum posts identified managing benzodiazepine withdrawal as a primary motivation for diclazepam use.[10] Users attempting to self-taper from prescription benzodiazepines with an unregulated compound risk establishing new dependence on a substance with no clinical monitoring and documented tablet content variability (0.59–1.39 mg versus declared 1 mg).[10]
Benzodiazepine withdrawal can be life-threatening — seizures represent the most serious acute complication. Medical withdrawal management options include supervised outpatient taper, inpatient stabilization, and adjunctive therapy.[21]
Cross-tolerance exists with all GABAergic substances: other benzodiazepines, alcohol, barbiturates, and Z-drugs.
Drug interactions
The primary interaction mechanism is additive or synergistic CNS and respiratory depression when combined with other depressants. All published diclazepam-associated fatalities involve polydrug combinations.
Opioid combinations carry the highest documented risk. Research on diclazepam–oxycodone combinations has demonstrated both direct additive respiratory depression and metabolic interactions that compound toxicity.[24] A fatal case involving diclazepam with the synthetic opioid U-47700 is documented.[17]
Alcohol produces additive GABA-A potentiation with elevated overdose risk. Other benzodiazepines produce cumulative depression; diclazepam's active metabolite delorazepam adds to the total benzodiazepine load. Barbiturates and Z-drugs carry additive respiratory depression risk.
Flumazenil (a benzodiazepine receptor antagonist) reverses diclazepam-induced sedation,[25][6] but its shorter half-life creates risk of resedation within 1–2 hours, potentially requiring repeated doses.[26] Flumazenil may trigger withdrawal seizures in physically dependent individuals.
Contraindications
No substance-specific contraindication studies have been conducted. The following apply by benzodiazepine class pharmacology:
Absolute contraindications:
- Concurrent opioid use without medical supervision — documented synergistic respiratory depression with fatality risk[24][17]
- Severe respiratory insufficiency — respiratory depression compounds existing ventilatory compromise
- Acute alcohol intoxication — additive CNS depression with aspiration and respiratory arrest risk
- Known hypersensitivity to benzodiazepines
Relative contraindications:
- Liver impairment — impaired clearance would prolong and intensify effects inferred
- History of substance use disorder — reinforcing properties confirmed;[5] high self-medication use documented[10]
- Pregnancy — benzodiazepines carry teratogenic and neonatal withdrawal risk inferred
- Myasthenia gravis — muscle relaxation may worsen neuromuscular dysfunction
- Sleep apnea — respiratory depression worsens obstructive and central apneic events
Harm Reduction[edit]
Forms & Identification
The tablet content variability documented in UK market analysis (0.59–1.39 mg per declared 1 mg unit) means that even within a single batch, doses can differ by more than double.[10] No reagent test reliably distinguishes diclazepam from other designer benzodiazepines — confirmatory identification requires laboratory-grade analytical techniques.
Powder forms present the highest dosing risk. At active doses below 2 mg, measurement error from a standard scale can represent a multiple of the intended dose. A precision milligram balance (0.001 g resolution) is the minimum tool for direct measurement; volumetric dosing in a measured solvent is more reliable.
Guidelines
- Test substance identity when possible. Reagent kits cannot confirm diclazepam specifically but can rule out some substitutions.
- Start at the lowest available dose and wait at least 3 hours before considering redosing — the slow onset and long duration make premature redosing a primary risk.
- Use volumetric dosing for powder forms. Dissolve a known weight in a measured volume of propylene glycol or another suitable solvent.
- Avoid combining with any other depressant — including alcohol, opioids, other benzodiazepines, or sleep medications.
- Inform a trusted person of the substance, dose, and timing.
- Secure valuables, lock away car keys, and remove access to additional substances before dosing — benzodiazepine disinhibition and amnesia create conditions for compulsive redosing.
Set & Setting
Diclazepam's extended duration (8–12 hours of perceived effects, with metabolite activity lasting days) requires planning for sustained impairment. Activities requiring coordination, judgment, or memory — driving, operating machinery, managing responsibilities — should be avoided for at least 24 hours after dosing, and longer after repeated use.
The delusions of sobriety effect is particularly relevant: users frequently underestimate their level of impairment. A sober companion aware of the timing and dose provides an external check against impaired self-assessment.
Aftercare & integration. Residual impairment from diclazepam and its active metabolites persists well beyond the period of perceived effects. Cognitive slowing, memory gaps, and impaired coordination may continue for 24–72 hours after a single dose.
Allow full recovery before driving, making significant decisions, or returning to work. Prioritize sleep, hydration, and regular meals during the recovery window. If amnesia occurred, reconstruct the timeline with a sober companion to identify any actions or communications made during the amnestic period. If diclazepam was used daily for more than a week, do not stop abruptly — abrupt benzodiazepine cessation carries seizure risk. Seek medical guidance for tapering.
Recovery & Support
Benzodiazepine dependence is a medical condition that responds to structured treatment. Recovery typically involves a gradual dose taper under medical supervision — abrupt cessation is dangerous and medically contraindicated after sustained use.
Resources for support include:
- Medical taper: A physician experienced in benzodiazepine withdrawal can design a tapering schedule. This is the safest path and the first step.
- SAMHSA National Helpline: 1-800-662-4357 (US) — free, confidential, 24/7 referral and information.
- Benzodiazepine Information Coalition: benzoinfo.com — peer support, medical provider directory, and tapering resources.
- BenzoBuddies: benzobuddies.org — peer community for people tapering or in recovery.
Self-tapering with unregulated diclazepam — despite its popularity for this purpose — substitutes one uncontrolled variable for another. Medical supervision provides dosing precision and seizure monitoring that self-management cannot replicate.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow or shallow breathing, blue-tinged lips or fingertips, unresponsiveness to voice or pain, vomiting while sedated, or seizures. These signs require immediate help — not observation.
Immediate steps:
- 1. Call emergency services.
- 2. Place the person in the recovery position (on their side) to prevent aspiration if they are breathing.
- 3. Do not induce vomiting.
- 4. Do not leave the person alone.
- 5. Monitor breathing continuously until help arrives.
What to tell the dispatcher: Name the substance (diclazepam or "a designer benzodiazepine"), the approximate dose and time taken, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect callers from prosecution.
Reversal: Flumazenil can reverse benzodiazepine sedation but is a hospital-administered drug. Its shorter half-life means sedation may return after 1–2 hours. In dependent users, flumazenil can trigger seizures.
Legal Status[edit]
Diclazepam has been progressively scheduled across major jurisdictions as designer benzodiazepines attracted regulatory attention. Initially unregulated in most countries, its increasing detection in forensic casework, poison control reports, and fatalities prompted legislative action beginning in 2015.
In the United States, diclazepam was temporarily placed in Schedule I effective July 2023.[27] Permanent Schedule I placement took effect on April 1, 2026.[9] The European Union adopted control measures via Council Decision (EU) 2024/832 on March 4, 2024.[8]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Permanently scheduled effective April 1, 2026; previously temporary Schedule I from July 2023[9] |
| United Kingdom | Class C, Schedule 2 (Misuse of Drugs Act 1971) | Controlled since June 2017; regulations amended 2024 |
| Germany | Anlage II (BtMG) | Scheduled November 21, 2015; license required for manufacture, possession, import, export, sale |
| European Union | EU-wide control measures | Council Decision (EU) 2024/832, March 4, 2024[8] |
| Canada | Schedule IV (CDSA) | All benzodiazepines scheduled by class |
| Sweden | Nationally controlled | Controlled as part of NPS benzodiazepine scheduling; STRIDA monitoring data available[28] |
| Australia | Status not confirmed | Insufficient data from available sources citation needed |
references
- [1] ^abcdMoustafa RE, Tarbah F, Saeed HS, Sharif SI (2021) Designer benzodiazepines versus prescription benzodiazepines: can structural relation predict the next step? — Critical Reviews in Toxicology doi:10.1080/10408444.2021.1907303
- [2]
- [3] ^abLuethi D, Liechti ME (2020) Designer drugs: mechanism of action and adverse effects — Archives of Toxicology doi:10.1007/s00204-020-02693-7
- [4]
- [5]
- [6]